Comparison · NCT00710554-782da43a
Sativex vs Placebo: Incidence of Adverse Events as a Measure of Subject's Safety.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sativex vs Placebo: Incidence of Adverse Events as a Measure of Subject's Safety. Trial comparisons, record NCT00710554-782da43a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00710554-782da43a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.852 | 0.78 | 0.903 | wilson | |
| Risk in group 2 | 0.703 | 0.616 | 0.778 | wilson | |
| Risk difference, group 1 minus group 2 | 0.148 | 0.0444 | 0.25 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.21 | 1.05 | 1.39 | log | |
| Odds ratio, group 1 over group 2 | 2.42 | 1.29 | 4.53 | log | |
| Number needed to treat, for one more participant with the outcome on Sativex than on Placebo | 6.75 | 4 | 22.5 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sativex | Each actuation delivered 100 μl (THC 2.7 mg and CBD 2.5 mg) up to a maximum of 24 actuations in any 24 hour period. | 109 | 128 | OG000 |
| Group 2 | Placebo | Each 100 ul actuation delivered the excipients plus colorants, up to a maximum of 24 actuations in any 24 hour period. | 83 | 118 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Incidence of Adverse Events as a Measure of Subject's Safety.
- Description
- The number of subjects that reported an adverse event in this study is presented.
- Time frame
- 19 weeks
- Population
- All subjects were included in this analysis.
Source ClinicalTrials.gov
Trial
- Title
- A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia
- NCT number
- NCT00710554
- Phases
- PHASE3
- Conditions
- Pain, Peripheral Neuropathy
- Interventions
- Sativex, Placebo
- Lead sponsor
- Jazz Pharmaceuticals
- Results first posted
- 2012-09-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00710554?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00710554-782da43a